Medical Condition News

RSS

Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with first line pancreatic cancer

Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.

1 Jul 2010

ResponseDX: Lung genetic test panel launched to detect EML4-ALK gene variants in lung cancer patients

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer.

1 Jul 2010

pSivida's licensee submits NDA to FDA for Iluvien

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a New Drug Application to the U.S. Food and Drug Administration for Iluvien for Diabetic Macular Edema.

1 Jul 2010

Studies link anti-cholesterol statin drugs to increased risk of anxiety and depression

Scientists are reporting a possible explanation for the symptoms of anxiety and depression that occur in some patients taking the popular statin family of anti-cholesterol drugs, and reported by some individuals on low-cholesterol diets. These symptoms could result from long-term, low levels of cholesterol in the brain, the report suggests. It appears in ACS' weekly journal Biochemistry.

1 Jul 2010

EIN News introduces new way for medical professionals, researchers to keep up with latest autism news

EIN News, one of the Internet's most popular online news-monitoring services, introduces a new way for medical professionals and researchers to keep up with the latest autism news.

1 Jul 2010

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Fero Industries, Inc. is pleased to announce that it has closed the acquisition of certain intellectual property and other associated rights related to the production, marketing, and distribution of Sucanon, a treatment for Type II diabetes.

1 Jul 2010

Bortezomib may offer hope for treating inflammatory diseases: New research

Those looking for a new treatment for a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory bowel disease, and lupus may need to look no further than a drug already available for treating cancer. In a research report published in the July 2010 print issue of the Journal of Leukocyte Biology, Japanese scientists use mice to show that bortezomib, currently used to treat cancers that affect white blood cells, induces cell death only in harmful (active and proliferating) T cells, leaving the rest unharmed.

1 Jul 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.

30 Jun 2010

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

Federal agencies, state governments take action to educate, protect against serious risks of indoor tanning

As the scientific evidence mounts, more federal agencies and state governments are taking action to educate and protect Americans against the serious risks of indoor tanning. Recent and pending legislation in numerous states restricting access to indoor tanning, along with the federal 10 percent indoor tanning tax that goes into effect on July 1, are important steps in keeping Americans safe from overexposure to ultraviolet (UV) radiation and the potential for future skin cancers.

30 Jun 2010

Grifols to acquire Pharmalink's Xepol programme for post-polio syndrome

Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.

30 Jun 2010

Sensor integrated insulin pump for better blood sugar control

Adding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes a study published on-line today in the New England Journal of Medicine.

30 Jun 2010

Medtronic's sensor-augmented insulin pump therapy provides superior glucose control, confirms STAR 3 study

In the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in type 1 diabetes, adult and pediatric patients using the Medtronic MiniMed Paradigm® REAL-Time System achieved better glucose control without an increase in hypoglycemia compared to multiple daily insulin injections (MDI), the most common approach to care today.

30 Jun 2010

New approach to lung cancer measurement holds promise for smokers

The pilot program for Lung Cancer Alliance's (LCA) website for patient donated scans is helping open the door to a potentially new method for evaluating lung cancer risk in smokers as well as non-smokers.

30 Jun 2010

Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs

Mirna Therapeutics announced today publication of new results in the journal Cancer Research demonstrating proof of concept that the systemic delivery of tumor suppressor microRNAs (miRNA) inhibits tumor growth by restoring the proper regulatory pathways required for cell cycle arrest and apoptosis.

30 Jun 2010

July 4th is approaching; ER departments are already beginning to treat firework injuries

In 2009, nearly 100 people in Illinois were rushed to hospitals with injuries caused by fireworks, according to the Office of the Illinois State Fire Marshall (OSFM).

30 Jun 2010

Renowned experts discuss new approaches to cancer therapy at international conference

An international conference attended by more than 70 of the world's leading experts and investigators in the field of Ephs and ephrins was held locally this week and hosted by Waldemar Debinski, M.D., Ph.D., director of the Brain Tumor Center of Excellence at Wake Forest University Baptist Medical Center.

30 Jun 2010

European Congress of Nephrology unveils results of various clinical trials

The 47th ERA-EDTA/DGfN congress in Munich has been the setting for a wide range of new clinical data. The results of the following clinical trials were presented at "Late-Breaking Clinical Trials Sessions."

30 Jun 2010

Tel Aviv University develops method for tracking progression of adult stem cells

It's a new technology that uses molecular therapy to coax adult cells to revert to an embryonic stem cell-like state, allowing scientists to later re-differentiate these cells into specific types with the potential to treat heart attacks or diseases such as Parkinson's.

30 Jun 2010

Medical Condition News

Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with first line pancreatic cancer

ResponseDX: Lung genetic test panel launched to detect EML4-ALK gene variants in lung cancer patients

pSivida's licensee submits NDA to FDA for Iluvien

Studies link anti-cholesterol statin drugs to increased risk of anxiety and depression

EIN News introduces new way for medical professionals, researchers to keep up with latest autism news

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Bortezomib may offer hope for treating inflammatory diseases: New research

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Federal agencies, state governments take action to educate, protect against serious risks of indoor tanning

Grifols to acquire Pharmalink's Xepol programme for post-polio syndrome

Sensor integrated insulin pump for better blood sugar control

Medtronic's sensor-augmented insulin pump therapy provides superior glucose control, confirms STAR 3 study

New approach to lung cancer measurement holds promise for smokers

Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs

July 4th is approaching; ER departments are already beginning to treat firework injuries

Renowned experts discuss new approaches to cancer therapy at international conference

European Congress of Nephrology unveils results of various clinical trials

Tel Aviv University develops method for tracking progression of adult stem cells

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News